Abstract
In the past decades many new drugs were approved for the treatment of cancer and have been established as essential parts of various therapeutic regimens. In particular targeted therapies and immune checkpoint inhibitors that aim at specific carcinogenic signaling pathways or modulate the tumor-immune response have revolutionized cancer therapy. Despite their targeted actions, these drugs may lead to diverse adverse reactions. In particular, cutaneous toxicities represent aserious threat to patients' quality of life and may lead to dose reduction or therapy cessation. In most cases, basic management is performed by the treating oncologist. Nevertheless, more severe reactions may require the expertise of adermatologist. In this review, we present specific cutaneous adverse reactions of new drug classes such as epidermal growth factor receptor inhibitors (EGFR-I), multikinase inhibitors (MKI), BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors (anti-PD1-, anti-CTLA4-antibodies). Furthermore, we give recommendations concerning the prevention and management of respective cutaneous reactions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
